Sign up to save your podcastsEmail addressPasswordRegisterOrContinue with GoogleAlready have an account? Log in here.
September 19, 2023Developing Best-in-Class Radiopharmaceuticals for Cancer Patients28 minutesPlayOur guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD.Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers....moreShareView all episodesBy Podcast Host Chris Leidli533 ratingsSeptember 19, 2023Developing Best-in-Class Radiopharmaceuticals for Cancer Patients28 minutesPlayOur guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD.Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers....moreMore shows like Rx for BiotechView allThe Readout Loud339 ListenersBiotech 2050 Podcast60 ListenersAll-In with Chamath, Jason, Sacks & Friedberg10,189 ListenersBusiness Of Biotech85 ListenersBioCentury This Week34 ListenersBiotech Hangout21 ListenersCell & Gene: The Podcast38 ListenersThe Biotech Startups Podcast24 ListenersThe BioCentury Show13 Listeners
Our guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD.Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers.
September 19, 2023Developing Best-in-Class Radiopharmaceuticals for Cancer Patients28 minutesPlayOur guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD.Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers....more
Our guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD.Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers.